[摘要] 目的：比较替格瑞洛和氯吡格雷在急性冠脉综合征（Acute c

[Abstract] Objective: To compare the effect of ticagrelor and clopidogrel in the treatment of acute coronary syndrome (ACS). Methods: 146 patients with ACS admitted to our hospital from February 2017 to January 2019 were selected as the research object, and they were divided into clopidogrel group and ticagrelor group according to the lottery method, 73 cases in each Percutaneous coronary intervention (PCI) and aspirin treatment, and then given clopidogrel and ticagrelor in two groups according to the grouping method, comparing the two groups before treatment and after 24h, 7d, and 28d Aggregation rate (Maximum platelet aggregation rate, MPAR), comparing the clinical efficacy of the two groups with major adverse cardiovascular events (MACE), bleeding rate Results: Before treatment, there was no significant difference in blood MPAR between the two groups (P> 0.05). After 24 hours, 7 days, and 28 days of treatment, the MPAR of the two groups decreased significantly (P <0.05), and the ticagrelor group was significantly lower than that before treatment. The clopidogrel group (P <0.05), and with time, the rate of decline in this group was significantly greater than the clopidogrel group (P <0.05); its treatment efficiency (91.78%) was significantly higher than that of the clopidogrel group (79.45% ); There was no significant difference in the incidence of MACE and bleeding between the two groups (P> 0.05). Conclusion: Compared with clopidogrel, ticagrelor has a more significant improvement effect on platelet aggregation status in ACS patients, and its clinical efficacy is significantly better than the former. <br>[Key words] acute coronary syndrome; ticagrelor; clopidogrel; platelet aggregation; efficacy; cardiovascular adverse events

Purpose: To compare the effects of tegreo and clopidogrel in the treatment of acute coronary syndrome (Acute coronary syndrome, ACS). Methods: 146 ACS patients admitted to the hospital from February 2017 to January 2019 were selected as study subjects, divided into chlorpyrifos and tegrelothe groups according to the drawing of lots, each of which was 73 cases, all patients were treated with percutan coronary artery intervention (Percutan coronary intervention, PCI) and aspirin treatment, followed by two groups of patients treated by group, respectively, by group method. Comparing the maximum concentration of platelets (Maximum platelet aggregation(AtPAR) after treatment 24h, 7d and 28d, the clinical efficacy of the two groups with the major cardiovascular adverse events (Major Adverse Cardiovascular Events, MACE), and the incidence of bleeding. Results: Before treatment, there was no significant difference between the two groups of blood MPAR (P.0.05), after treatment of 24h, 7d, 28d, both groups of MPAR decreased significantly compared to pre-treatment (P 0.05), and the tigillo group was significantly lower than The Clopidogret group (P 0.05), which declined significantly over time than the Clopidogret group (P0.05); There was no significant difference between the two groups of MACE and the incidence of bleeding (P.0.05). Conclusion: Compared with clopidogrel, the improvement effect of platelet aggregation in ACS patients was more significant, and the clinical effect was significantly better than that of the former.<br>Acute coronary syndrome; Tigrelo; Clopidogrer; platelet aggregation; efficacy; cardiovascular adverse events

[Abstract] Objective: To compare the effect of tigril and clopidogrel in the treatment of acute coronary syndrome (ACS). Methods: 146 ACS patients admitted to our hospital from February 2017 to January 2019 were selected as the research objects. According to the method of drawing lots, they were divided into two groups: clopidogrel group and tegrarol group, 73 cases in each group. All patients underwent percutaneous coronary intervention After PCI and aspirin treatment, two groups of patients were treated with clopidogrel and tegrarol respectively according to the grouping method. The maximum platelet aggregation rate (mpar) before treatment and after 24, 7 and 28 days of treatment were compared between the two groups. The clinical efficacy and major adverse cardiovascular events were compared between the two groups Events, Mace), the incidence of bleeding. Results: there was no significant difference in mpar between the two groups before treatment (P > 0.05). 24 hours, 7 days and 28 days after treatment, mpar in the two groups was significantly lower than that before treatment (P < 0.05), and the rate of decline in the tegrilol group was significantly higher than that in the clopidogrel group (P < 0.05), and the effective rate of treatment (91.78%) was significantly higher than that in the clopidogrel group (P < 0.05) There was no significant difference in the incidence of mace and bleeding between the two groups (P > 0.05). Conclusion: compared with clopidogrel, tegrarol has more significant effect on improving platelet aggregation in ACS patients, and its clinical effect is better than the former.<br>[Key words] acute coronary syndrome; tegrarol; clopidogrel; platelet aggregation; efficacy; cardiovascular adverse events<br>